Related Experiment Video
Updated: Nov 9, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotic Management of Elderly Patients With Coronary Artery Disease
Piera Capranzano1, Dominick J Angiolillo2
1Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy.
Insights
Elderly patients with coronary artery disease (CAD) face higher risks of both blood clots and bleeding. Optimal antithrombotic therapy must balance efficacy and safety for this population.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Antithrombotic therapy is crucial for managing coronary artery disease (CAD), especially in elderly patients.
- Elderly individuals with CAD have an elevated risk of ischemic events and bleeding complications.
- Age-related physiological changes and polypharmacy complicate antithrombotic drug management in older adults.
Purpose of the Study:
- To review current data on antithrombotic therapy in elderly patients with CAD.
- To highlight the unique challenges in managing antithrombotic treatment in this demographic.
- To inform clinical practice and identify research gaps for optimizing care.
Main Methods:
- Systematic review of existing literature on antithrombotic therapy in elderly CAD patients.
- Analysis of factors influencing thrombotic and bleeding risks in older adults.
- Evaluation of pharmacokinetic and pharmacodynamic alterations of antithrombotic drugs with age.
Main Results:
- Elderly patients exhibit complex risk-benefit profiles for antithrombotic agents due to increased vulnerability to both thrombosis and hemorrhage.
- Age-related changes impact drug metabolism and response, necessitating tailored therapeutic approaches.
- Concurrent conditions like atrial fibrillation further complicate treatment decisions.
Conclusions:
- Careful consideration of individual patient factors is essential for safe and effective antithrombotic therapy in older adults with CAD.
- Developing antithrombotic strategies that minimize bleeding risk while maintaining efficacy is a critical unmet need.
- Further research is required to establish optimal treatment guidelines for this growing patient population.
Abstract:
Antithrombotic therapy represents the mainstay of treatment in patients with coronary artery disease (CAD), including elderly patients who are at increased risk for ischemic recurrences. However, the elderly population is also more vulnerable to bleeding complications. Numerous mechanisms, including abnormalities in the vasculature, thrombogenicity, comorbidities, and altered drug response, contribute to both increased thrombotic and bleeding risk. Age-related organ changes and drug-drug interactions secondary to polypharmacy lead to distinct pharmacokinetic and pharmacodynamic profiles of antithrombotic drugs. Overall these factors contribute to the risk-benefit profiles of antithrombotic therapies in elderly subjects and underscore the need for treatment regimens that can reduce bleeding while preserving efficacy. Given that the prevalence of CAD, as well as concomitant diseases with thromboembolic potential, such as atrial fibrillation, increases with age and that the elderly population is in continuous growth, understanding the safety and efficacy of different antithrombotic regimens is pivotal for patient-centered care. In the present overview the authors appraise the available data on the use of antithrombotic therapy in older patients with CAD to assist with the management of this high-risk population and define knowledge gaps that can set the basis for future research.
Related Concept Videos
01:26Angina IV: Management
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Atherosclerosis III: Management
01:29Venous Thrombosis III: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures